Staphylococcal Infections Clinical Trial
Official title:
Biofilm Formation Increases Treatment Failure in Staphylococcus Epidermidis Device-related Osteomyelitis in Human Patients
This was a prospective study performed between November 2011 and September 2013. Patients
with a confirmed S. epidermidis infection after fracture fixation or prosthetic joint
infection were included. Exclusion criteria included infections involving external fixation
pins, infections without any implanted hardware and culture positive patients not displaying
any clinical sign of infection. The following surgical parameters were documented: affected
bone or joint; type of implant; time between implantation of the device and onset of
symptoms. Personal characteristics and patients`health status were also documented. Any
revision surgeries involving the site of interest and all isolated pathogens were recorded
throughout the course of treatment and follow-up.
A follow up examination was performed an average of 26 months after discharge. Primary
outcome at follow up was cure. Cure was define by the authors as: missing local (at site of
interest) or systemic signs of infection, terminated surgical and systemic therapy and
restoration of joint or limb function.
At the first surgical procedure after enrolment, at least four deep bone biopsies were taken
from the interface between implant and affected bone. Identification and antibiotic
susceptibility testing of all growth was performed. Multi-drug-resistance (MDR) was defined
according to the definitions of the European Committee of Antimicrobial Susceptibility
Testing (EUCAST). Biofilm formation was analysed and quantified in microtitre plate assays
according to protocol of Stepanovic et al.(see references).
This was a prospective study performed between November 2011 and September 2013. All
patients provided informed written consent prior to inclusion in the study. Inclusion
criteria were deep S. epidermidis infections after fracture fixation or prosthetic joint
surgery. Fracture fixation infections includes fractures involving the long bones as well as
the pelvis and the spine. Bacterial growth at the site of interest in combination with
either pseudarthrosis, implant-loosening/failure or local and systemic signs of surgical
site infection were required for inclusion. Exclusion criteria included infections involving
external fixation pins, infections without any implanted hardware and culture positive
patients not displaying any clinical sign of infection.
Upon entry into the study, the following surgical parameters were documented: affected bone
or joint; type of implant; time between implantation of the device and onset of symptoms.
Personal characteristics were also documented and included: gender; age; body mass index
(BMI); smoker/non-smoker; overall medical condition (Charlson comorbidity index); and
chronic immunosuppressive conditions (Diabetes mellitus, chronic alcoholism, Child`s class C
cirrhosis, neoplasia, transplantation, AIDS and steroid medication). Any revision surgeries
involving the site of interest and all isolated pathogens were recorded throughout the
course of treatment and follow-up.
A follow up examination was performed an average of 26 months after discharge. Primary
outcome at follow up was cure. Cure was define by the authors as: missing local (at site of
interest) or systemic signs of infection and terminated surgical and systemic therapy.
At the first surgical procedure after enrolment, at least four deep bone biopsies were taken
from the interface between implant and affected bone. The tissue samples were placed in a
sterile container with thioglycollate liquid medium (bioMérieux, Hazelwood, MO, USA). The
samples were cultured for ten days at 37°C and examined each day macroscopically. Any growth
was inoculated onto a blood agar plate (bioMérieux, Hazelwood, MO, USA) for further growth
and subsequent identification. In all cases, additional swabs and soft tissue samples may
have been taken as per clinical routine, however, only samples adjacent to the implant were
used for diagnosis in this study.
Identification and antibiotic susceptibility testing of all growth was performed using a
Vitek2 (bioMerieux Vitek Inc, Hazelwood, MO, USA). Multi-drug-resistance (MDR) was defined
according to the definitions of the European Committee of Antimicrobial Susceptibility
Testing (EUCAST). Oxacillin resistance was used as an indicator for methicillin resistant S.
epidermidis (MRSE).
Biofilm formation was analysed and quantified in microtitre plate assays according to the
well-established protocol of Stepanovic et al.(see references). This method traditionally
assigns isolates to one of four categories: non-biofilm-formers and weak, moderate or strong
biofilm-formers.
The key variables with regards to bacterial phenotype were: biofilm formation; methicillin
resistance; and multidrug resistance. The primary outcome measure was whether the infection
was "cured" or not. Primary outcome parameters were calculated as a function of all patients
for whom data was complete. Statistical comparison was restricted to the lower extremity
cohort since the other patients are not scored for many of the functional outcome measures
and as such incomplete.
Univariate logistic regression models were used to determine the influence of each
prognostic factor (obesity, smoking, diabetes mellitus, chronic immune suppression, open
fracture (initially), early onset infection, biofilm formation, methicillin resistance, MDR
and Charlson comorbidity index) on cure. P-values <0.05 were considered significant.
Statistical analyses were performed using SAS software (Version 9.2; Cary, NC, USA).
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01447407 -
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
|
Phase 1 | |
Recruiting |
NCT00518076 -
Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant
|
N/A | |
Completed |
NCT01324440 -
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
|
Phase 1 | |
Completed |
NCT00501150 -
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
|
N/A | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00063089 -
Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever
|
Phase 1/Phase 2 | |
Completed |
NCT00175370 -
Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus
|
N/A | |
Recruiting |
NCT03456544 -
Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
|
||
Completed |
NCT02557568 -
Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne
|
N/A | |
Terminated |
NCT01196169 -
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty
|
Phase 4 | |
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Completed |
NCT02971657 -
Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients` Clinical Outcome in Orthopedic Device Related Bone Infections
|
N/A | |
Completed |
NCT00303069 -
V710 First-In-Man (FIM) Study (V710-001)
|
Phase 1 | |
Completed |
NCT00156377 -
Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections
|
Phase 4 | |
Completed |
NCT00631566 -
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
|
N/A | |
Completed |
NCT00113191 -
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
|
N/A | |
Completed |
NCT02782078 -
Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections
|
N/A | |
Completed |
NCT00859677 -
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
|
||
Completed |
NCT00211900 -
Evaluation of Manufacturing Lot of StaphVAX
|
Phase 3 | |
Completed |
NCT02492958 -
SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults
|
Phase 2 |